Published
January 18, 2024

Adj Fosfomycin

icon-benefit
HomeSubstudies
Adj Fosfomycin

This substudy will investigate the effectiveness of combination therapy consisting of antistaphylococcal cell-wall active agents plus adjunctive fosfomycin vs. standard monotherapy in patients with Staphylococcus aureus bloodstream infections at high risks of complications or relapse.

Substudies in Progress

SNAP Trial

SABSI

Profiling the genetic and epigenetic determinants that predispose to severe manifestations of Staphylococcus aureus bacteremia

icon-benefit
All Interested
icon-benefit
Substudy in Progress

cfDNA

Cell-free DNA is a Versatile Analyte to Monitor Complications and Guide Treatment Duration in Staphylococcus aureus Bacteremia

icon-benefit
Any interested
icon-benefit
Substudy in Progress

SABSI-Outcomes

Derivation and Validation of Phenotypes of Staphylococcus aureus bloodstream infection, with Correlation with Outcome.

icon-benefit
Any Interested
icon-benefit
Substudy in Progress

SNAP-SEQ

Pilot study for real-time sequencing of Staphylococcus aureus bloodstream isolates

icon-benefit
Any Interested
icon-benefit
Substudy in Progress

PENFAST

Using a validated penicillin allergy risk prediction tool (Pen-FAST) in patients with a low risk penicillin allergy 

icon-benefit
Any Interested
icon-benefit
Substudy in Progress

Pharmacogenomics

 Immunopathogenesis and pharmacogenomics of severe antibiotic hypersensitivity 

icon-benefit
Australia
icon-benefit
Substudy in Progress
BACK TO TOP